Genus plc (LON:GNS – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 2,160 ($28.75) and last traded at GBX 2,150 ($28.61), with a volume of 25118 shares changing hands. The stock had previously closed at GBX 2,110 ($28.08).
Wall Street Analysts Forecast Growth
Separately, Shore Capital reaffirmed a “buy” rating on shares of Genus in a research note on Wednesday, April 30th.
Get Our Latest Research Report on GNS
Genus Stock Performance
Genus (LON:GNS – Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.53) earnings per share (EPS) for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, sell-side analysts forecast that Genus plc will post 70.9644323 EPS for the current year.
Insider Activity
In related news, insider Jorgen Kokke sold 19,967 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($23.04), for a total transaction of £345,628.77 ($459,979.73). 0.75% of the stock is owned by company insiders.
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Further Reading
- Five stocks we like better than Genus
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tesla: Get Ready To See It Trading Above $400 Again
- What Investors Need to Know to Beat the Market
- ON Holding Surges, Leads High-End Retailers Into Reversal
- What is a Low P/E Ratio and What Does it Tell Investors?
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.